Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS proposes to cover PET scans for staging cervical cancer

This article was originally published in The Gray Sheet

Executive Summary

Under Aug. 13 proposed decision, the Medicare agency would lift data collection requirements for positron emission tomography scans of cervical cancer patients when used to make "meaningful changes in therapeutic management." The proposal limits coverage to one PET scan with the radioactive tracer F-18 fluorodeoxyglucose when needed to locate a tumor or determine the extent of the tumor in specific therapeutic situations. CMS also proposes non-coverage of PET in diagnosing cervical cancer (1"The Gray Sheet" June 15, 2009). The agency opened the coverage analysis May 8 at the request of two oncology professors (2"The Gray Sheet" May 18, 2009). Comments are due Sept. 12, and the agency plans a final ruling by Nov. 11

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel